The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause

Letrozole, an aromatase inhibitor, is ineffective in the presence of ovarian estrogen production. Two subpopulations of apparently postmenopausal women might derive reduced benefit from letrozole due to residual or returning ovarian activity: younger women (who have the potential for residual subcli...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Breast Cancer Res Treat
Auteurs principaux: Chirgwin, Jacquie, Sun, Zhuoxin, Smith, Ian, Price, Karen N., Thürlimann, Beat, Ejlertsen, Bent, Bonnefoi, Hervé, Regan, Meredith M., Goldhirsch, Aron, Coates, Alan S.
Format: Artigo
Langue:Inglês
Publié: 2011
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4802157/
https://ncbi.nlm.nih.gov/pubmed/21892704
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-011-1741-6
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires